Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINE‐HF</scp> trial

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to reduce the risk of cardiovascular death or worsening heart failure (HF), and improve symptom burden, physical function quality life in patients with HF reduced ejection fraction. The mechanisms benefits SGLT2 inhibitors, however, remain unclear. In this substudy DEFINE-HF trial, randomized dapagliflozin placebo had lung fluid volumes (LFVs) measured by remote dieletric sensing at baseline after 12 weeks therapy. A significantly greater proportion dapagliflozin-treated (as compared placebo) experienced improvement LFVs fewer no change deterioration treatment. To our knowledge, is first study suggest a direct effect (or any inhibitor) on more effective “decongestion”, contributing meaningful way ongoing debate regarding inhibitor benefits.